Urology

Recurrence rates remain a concern, with up to one third of men experiencing disease return within two years.

Recent advances in three-dimensional (3D) culture technology have transformed the way researchers study bladder cancer.

One promising approach targets nectin-4, a cell adhesion molecule linked to poor outcomes in several cancers, including bladder cancer.

A predictive scoring system, incorporating both current and prior PSA values, revealed that patients with persistently elevated levels had a very low likelihood, under 10%, of their PSA decreasing below the threshold at follow-up.

Black men remain underrepresented in large screening trials, and screening rates declined across all groups after the 2012 US Preventive Services Task Force recommendations.

nalysis of the BLADDA urothelial cancer registry demonstrated that neoadjuvant chemotherapy was associated with reduced risk of invasive bladder cancer recurrence.

Results showed that bpMRI was noninferior to mpMRI for detecting clinically significant prostate cancer, defined as Gleason Grade Group 2 or higher.

By aligning pretreatment risk stratification more closely with AS eligibility, clinicians may feel more confident recommending surveillance, potentially reducing overtreatment.